The plasma disappearance rate of indocyanine green was examined after prostaglandin E1 administration in 11 patients with chronic liver disease. The patients were divided into two groups according to the presence (n = 6) or absence (n = 5) of liver cirrhosis. Indocyanine green (0.1 mg/kg) was introduced as an intravenous bolus 5 min after prostaglandin E1 administration and the disappearance rate of indocyanine green (ICG-K) was determined by a finger-monitoring method. Saline was injected as the control. Prostaglandin E1 administration increased ICG-K, and this response was dose dependent when the prostaglandin E1 dose ranged from 0.01 to 0.05 μg/kg/min. When ICG-K after prostaglandin E1 relative to the ICG-K after saline (the control) was defined as the ICG-K ratio, the ICG-K ratio in the liver cirrhosis group was higher than that in the group without cirrhosis. These findings suggest that prostaglandin E1 increases the ICG-K of patients with chronic liver disease, and that this is strongest in patients with liver cirrhosis.
CaesarJShaldonSChiandussiLThe use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci1961; 21: 43–57.
2.
LeevyCMMendenhallCLLeskoWEstimation of hepatic blood flow with indocyanine green. J Clin Invest1962; 41: 1169–1179.
3.
MerkelCBolognesiMFinucciGFIndocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. J Hepatol1989; 9: 16–22.
4.
HemmingAWScudamoreCHShackletonCRIndocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg1992; 163: 515–518.
5.
JalanRPlevrisJNJalanARA pilot study of indocyanine green clearance as an early predictor of graft function. Transplantation1994; 58: 196–200.
6.
AbecassisMFalkRBlendisL Treatment of fulminant hepatic failure with a continuous infusion of prostin VR (PGE1). Hepatology1987; 7: 1104.
7.
TanabeGAikouTKuritaKEffects of exogenous prostaglandin E1 in hepatectomized patients. J Hep Bil Pancr Surg1994; 4: 402–405.
8.
GreigPDWoolfGMSinclairSB Treatment of primary liver graft nonfunction with prostaglandin E1. Transplantation1989; 48: 447–453.
9.
TakayaSIwakiYStarzlTE Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. Transplantation1992; 54: 927–929.
10.
NishidaOMoriyasuFNakamuraTRelationship between splenic and superior mesenteric venous circulation. Gastroenterology1990; 98: 712–725.
11.
TsukadaKKatohHIgaY Prostaglandin E1 enhances hepatic portal venous flow by dilating the portal vascular bed in 70% hepatectomized dog. Gastroenterol Jpn1992; 27: 341–347.
12.
NakadairaKTsukadaKSakaguchiT A pharmacological analysis of prostaglandin E1 on portal blood flow after partial hepatectomy in rats. Surg Today1993; 23: 277–279.
13.
TsukadaKSakaguchiTTomiyamaT Enhanced hepatic portal blood flow induced by prostaglandin E1 following liver transplantation in pigs. Surg Today1994; 24: 621–626.
14.
MizoguchiYTsutsuiHMiyajimaK The protective effects of prostaglandin E1 in an experimental massive hepatic cell necrosis model. Hepatology1987; 7: 1184–1188.
15.
BeckPLMcKnightGWKellyJK Hepatic and gastric cytoprotective effects of long-term prostaglandin E1 administration in cirrhotic rats. Gastroenterology1993; 105: 1483–1489.
16.
ShimadaMMatsumataTAdachiEEstimation of degree of liver cirrhosis using a fibrosis score; a multivariate analysis of clinical parameters and resected specimens. Hepatogastroenterology1994; 41: 177–180.
17.
MericanISprengersDMcCormickPADiurnal pattern of variceal bleeding in cirrhotic patients. J Hepatol1993; 19: 15–22.
18.
AonoTTsukadaKSakaguchiTUtilization of low dose indocyanine green test for evaluating liver function. Acta Med Biol1994; 42: 165–169.
19.
IshigamiYMasuzawaMMiyoshiEClinical applications of ICG finger monitor in patients with liver disease. J Hepatol1993; 19: 232–240.
20.
NakayamaMKanayaNFujitaSEffects of ephedrine on indocyanine green clearance during spinal anesthesia: evaluation by the finger piece method. Anesth Analg1993; 77: 947–949.
21.
AonoTTsukadaKSakaguchiTNoticeable hyperbilirubinemia following major hepatectomy in patients with biliary tract carcinoma. Arch Jpn Chir64: 1995 (in press).
22.
AonoJTakedaAUedaW Interaction of halothane and PGE1 on ICG excretion. Masui (in Japanese)1990; 39: 588–591.
23.
GelmanSIDisturbances in hepatic blood flow during anesthesia and surgery. Arch Surg1976; 111: 881–883.
24.
StrongCGBohrDF Effects of prostaglandins E1, E2, A1, and F1α on isolated vascular smooth muscle. Am J Physiol1967; 213: 725–733.
25.
AdachiHSugiharaHNakagawaH Effect of prostaglandin E1 on fractional distribution of cardiac output and organ blood flow in man: a simultaneous and non-invasive determination using double dose thallium-201 scintigraphy. Cardiovasc Res1984; 18: 657–662.
26.
BhathalPSGrossmanHJReduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol1985; 1: 325–337.
27.
BergstromSDunerHEulerUSObservations on the effects of infusion of prostaglandin E in man. Acta Physiol Scand1959; 45: 145–151.
28.
EklundBCarlsonLACentral and peripheral circulatory effects and metabolic effects of different prostaglandins given i.v. to man. Prostaglandins1980; 20: 333–347.
